AstraZeneca PLC (NASDAQ:AZN) Shares Bought by XML Financial LLC

XML Financial LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 11.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,398 shares of the company’s stock after buying an additional 650 shares during the period. XML Financial LLC’s holdings in AstraZeneca were worth $419,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AZN. FMR LLC raised its position in shares of AstraZeneca by 1.1% during the 3rd quarter. FMR LLC now owns 23,117,447 shares of the company’s stock worth $1,801,080,000 after buying an additional 258,477 shares in the last quarter. Franklin Resources Inc. raised its holdings in AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after purchasing an additional 1,522,715 shares in the last quarter. Fisher Asset Management LLC lifted its position in AstraZeneca by 5.3% in the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after purchasing an additional 524,175 shares during the period. Clearbridge Investments LLC boosted its stake in AstraZeneca by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after purchasing an additional 186,010 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of AstraZeneca by 109.6% during the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after purchasing an additional 1,605,758 shares during the period. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 0.4 %

Shares of AZN opened at $68.20 on Thursday. The business’s 50-day moving average price is $66.20 and its 200 day moving average price is $74.32. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $211.49 billion, a P/E ratio of 32.63, a P/E/G ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business earned $0.87 earnings per share. The firm’s revenue was up 18.0% compared to the same quarter last year. Analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.